Hormone medicines
Menotropins (hMG)
Human menopausal gonadotropins provide FSH and LH activity; more retrieved eggs do not automatically mean more ongoing pregnancies.
Randomized assessor-blinded IVF evidence; no demonstrated pregnancy superiority; checked 2026-10-01
Also known as: hMG · Menopur · Human menopausal gonadotropin
Practical use
Clinical purpose, evidence and review questions
- Keep outcome stages separate
- Compare eggs, embryos, ongoing pregnancies and live births as different measures.
- Ask about the applicable population
- Check whether the study pathway resembles the clinical situation being discussed.
- Prepare previous response records
- Bring earlier follicle response, adverse effects and treatment names to review.
Overview
Menotropins, often called hMG, are gonadotropin preparations with FSH and LH activity. US Menopur is indicated for multiple-follicle development and pregnancy in ovulatory women undergoing assisted reproductive technology. This product-specific indication should not be expanded to every use described for all hMG preparations.
Risks and limitations
Risks include ovarian hyperstimulation, enlargement or torsion, multiple pregnancy and pulmonary or vascular complications. Primary ovarian failure, pregnancy, unexplained bleeding and certain tumors are contraindications. Severe pelvic pain, swelling, breathlessness or reduced urination needs prompt fertility-team assessment.
How to read this
One medicine can yield fewer eggs yet a different embryo-quality pattern. The endpoint closest to the patient’s goal should carry more weight than selecting whichever intermediate number looks largest.
Research explained
MERIT: highly purified hMG versus recombinant FSH
Who was studied
731 women randomized to highly purified hMG (363) or recombinant FSH (368) in a multinational IVF study with a GnRH-agonist pathway and assessor blinding.
What was found
Recombinant FSH yielded more oocytes on average (11.8 versus 10.0), while hMG had a higher proportion of top-quality embryos. Ongoing pregnancy per cycle was 27% with hMG versus 22% with recombinant FSH; odds ratio 1.25 (95% CI 0.89–1.75).
What it cannot establish
Noninferiority was established, but pregnancy superiority was not. Egg counts and embryo-quality measures cannot be treated as direct substitutes for live birth.
Read the original studyIntermediate outcomes can disagree
The treatment producing more eggs was not the one with the higher numerical ongoing-pregnancy proportion. This illustrates why endpoint selection matters.
Supporting sourceKnow what the named preparation contains
Menotropin preparations provide gonadotropin activity through a specified manufactured product. Product identity, indication and prior clinical response belong together.
Supporting sourceClaims versus findings
Not established
Twenty-seven versus twenty-two percent proves superior pregnancy success.
The confidence interval included no difference, and the authors did not conclude superiority.
Check the evidenceCommon questions
Did this study show that more eggs always improve outcomes?
No. The egg-yield and pregnancy findings point to the limits of that assumption.
SourceSources
MERIT: highly purified hMG versus recombinant FSH
US prescribing information; checked October 1, 2026
Sources checked 2026-10-01.
General education; not a personal treatment plan.